english Icono del idioma   español Icono del idioma  

Por favor, use este identificador para citar o enlazar este ítem: https://hdl.handle.net/20.500.12008/52137 Cómo citar
Título: Determination of “borderline resectable” pancreatic cancer – A global assessment of 30 shades of grey
Autor: Badgery, Henry E.
Muhlen-Schulte, Tjuntu
Zalcberg, John Raymond
D'souza, Bianka
Gerstenmaier, Jan F.
Pickett, Craig
Samara, Jaswinder Singh
Croagh, Daniel G.
Ahmed, Farhan
Allan, Emel
Amelina, Inna
Aroori, Somaiah
Balendran, Nalayini
Chu, Linda C.H.
Carnelli, Carlos
Tipo: Artículo
Descriptores: NEOPLASIAS PANCREÁTICAS, PRONÓSTICO, TERAPÉUTICA, TOMOGRAFÍA
Fecha de publicación: 2023
Resumen: Background: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with a poor prognosis. Accurate preoperative assessment using computed tomography (CT) to determine resectability is crucial in ensuring patients are offered the most appropriate therapeutic strategy. Despite the use of classification guidelines, any interobserver variability between reviewing surgeons and radiologists may confound decisions influencing patient treatment pathways. Methods: In this multicentre observational study, an international group of 96 clinicians (42 hepatopancreatobiliary surgeons and 54 radiologists) were surveyed and asked to report 30 pancreatic CT scans of pancreatic cancer deemed borderline at respective multidisciplinary meetings (MDM). The degree of interobserver agreement in resectability among radiologists and surgeons was assessed and subgroup regression analysis was performed. Results: Interobserver variability between reviewers was high with no unanimous agreement. Overall interobserver agreement was fair with a kappa value of 0.32 with a higher rate of agreement among radiologists over surgeons. Conclusion: Interobserver variability among radiologists and surgeons globally is high, calling into question the consistency of clinical decision making for patients with PDAC and suggesting that central review may be required for studies of neoadjuvant or adjuvant approaches in future as well as ongoing quality control initiatives, even amongst experts in the field.
Editorial: Elsevier
EN: HPB. Nov. 2023;25(11):1393-1401
Citación: Badgery H, Muhlen-Schulte T, Zalcberg J y otros. Determination of “borderline resectable” pancreatic cancer – A global assessment of 30 shades of grey. HPB [en línea] . Nov. 2023;25(11):1393-1401
ISSN: 1477-2574
Licencia: Licencia Creative Commons Atribución - No Comercial - Sin Derivadas (CC - By-NC-ND 4.0)
Aparece en las colecciones: Publicaciones Académicas y Científicas - Facultad de Medicina

Ficheros en este ítem:
Fichero Descripción Tamaño Formato   
Determination of borderline resectable pancreatic cancer.pdfDetermination of borderline resectable pancreatic cance767,56 kBAdobe PDFVisualizar/Abrir


Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons Creative Commons